Sign In
Buy BYSI
$1.15
+0.0200 (+1.77%)
At Close: Jul 31, 2026
BYSI Stock: Why Did BeyondSpring Gain 15% on Tuesday?
03:29pm, Tuesday, 31'st Aug 2021
Today, some very positive news surrounding BeyondSpring's lead drug candidate has sent shares of BYSI stock soaring. The post BYSI Stock: Why Did BeyondSpring Gain 15% on Tuesday?
Why BeyondSpring Stock Is Soaring This Week
09:50am, Friday, 27'th Aug 2021
A lucrative partnership deal with a pharmaceutical giant in China bodes well for BeyondSpring's potential new blockbuster cancer drug.
BeyondSpring Inks Plinabulin Agreement In Greater China
09:20am, Thursday, 26'th Aug 2021
BeyondSpring Inc (NASDAQ: BYSI) and Jiangsu Hengrui Pharmaceuticals Co Ltd have entered into an exclusive commercialization and co-development agreement for plinabulin in Greater China. In combin
BYSI Stock: Over 4% Increase Pre-Market Explanation
07:32am, Thursday, 26'th Aug 2021
The stock price of BeyondSpring (NASDAQ: BYSI) increased by over 4% pre-market. This is why it happened.
NEW YORK and SHANGHAI, China, Aug. 26, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of can
This Biotech Stock Just Skyrocketed by 170%. Is It a Buy?
05:19am, Tuesday, 10'th Aug 2021
Don't be too quick to pull the trigger.
A small biopharma stock soars 198% after the company says it will seek FDA approval following a successful cancer-drug trial
02:35pm, Wednesday, 04'th Aug 2021
BeyondSpring surged 197% Wednesday after announcing it is seeking FDA approval for its cancer drug.
These 2 Soaring Biotech Stocks Are Making the Nasdaq Stronger
01:10pm, Wednesday, 04'th Aug 2021
The Nasdaq Composite is holding up better than its fellow market benchmarks.
BYSI Stock Price Increases Over 320% Pre-Market: Why It Happened
08:20am, Wednesday, 04'th Aug 2021
The stock price of Beyondspring Inc (NASDAQ: BYSI) increased by over 320% pre-market. This is why it happened.
NEW YORK, Aug. 04, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, an
BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space
11:00pm, Saturday, 31'st Jul 2021
BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other.
BeyondSpring Strengthens Board with the Addition of Ex-Immunomedics and Constellation Commercial Head Brendan Delaney
07:30am, Wednesday, 14'th Jul 2021
NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- BeyondSpring (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global pharmaceutical company focused on the development of cancer therapeutics, to
BeyondSpring to Participate in the William Blair Biotech Focus Conference
08:00am, Thursday, 08'th Jul 2021
NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (“BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today a
BeyondSpring to Host R&D Day to Discuss Novel Immune Agent Plinabulin's Development Program in Anti-cancer Indications
04:00pm, Thursday, 17'th Jun 2021
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative canc
BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q1 2021 Results - Earnings Call Transcript
02:36pm, Wednesday, 16'th Jun 2021
BeyondSpring Inc. (BYSI) CEO Dr. Lan Huang on Q1 2021 Results - Earnings Call Transcript
